MASS-FIX detects M-protein related kidney disease    

Monoclonal gammopathy of renal significance

Renal disorders caused by monoclonal immunoglobin (IgM) lack the malignant implications of hematologic plasma cell disorders; however, they are associated with increased morbidity due to the severity of renal (sometimes systemic) lesions caused by IgM. Low occurrence of monoclonal gammopathy of renal significance (MGRS) has resulted in poorly defined best-practices for testing in patients with chronic kidney disease. 

Innovation improves diagnosis and outcomes

Utilizing highly sensitive, MALDI-TOF mass spectrometry to detect IgM, or M-proteins, facilitates diagnosis across a spectrum of IgM-associated renal disorders, including AL amyloidosis, proliferative glomerulonephritis with monoclonal Ig deposits, and C3 glomerulopathy. Early identification of MGRS is vital since targeted suppression of IgM secretion through chemotherapy frequently improves outcomes.

Superior testing for optimal patient care

The new MASS-FIX testing method provides:

  • Verifying if a patient’s IgG kappa mass is caused by monoclonal therapeutics or residual disease
  • Convenient, clinically relevant information
  • Industry-leading turnaround times for results

Test menu

Screening and diagnosis

DMOGA  | Monoclonal Gammopathy, Diagnostic, Serum

Analytic time: 2 days  

Appropriate ordering scenario 

  • Assessing the risk of progression from MGUS to multiple myeloma 

PEISO  | Protein Electrophoresis and Isotype, Serum

Analytic time: 2 days  

Appropriate ordering scenario 

  • Diagnosis of monoclonal gammopathies, when used in conjunction with serum free light-chain studies performed at client site 

MALD  | M-Protein Isotype, Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry, Serum

Analytic time: Same day/1 day 

Appropriate ordering scenario 

  • When protein electrophoresis and free light-chain testing is performed in-house; M-protein isotyping by MASS-FIX only 

Learn more about how to order these tests at your institution.

Relevant publications from Mayo Clinic

  • Leung N, Bridoux, F, Nasr, SH. Monoclonal Gammopathy of Renal Significance. NEJM. 2021;384:1931-1941
  • Milani P Murray DL, Barnidge DR, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92:772-779.
  • Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive assessment of M-protiens using nanobody enrichment coupled to MALDI-TOF mass specrometry. Clin Chem. 2016 Oct;62(10):1334-1344.